AR081992A2 - FORMA POLIMORFICA g DE RIFAXIMINA, PROCESOS PARA SU PRODUCCION Y SUS COMPOSICIONES FARMACEUTICAS - Google Patents

FORMA POLIMORFICA g DE RIFAXIMINA, PROCESOS PARA SU PRODUCCION Y SUS COMPOSICIONES FARMACEUTICAS

Info

Publication number
AR081992A2
AR081992A2 ARP110102194A ARP110102194A AR081992A2 AR 081992 A2 AR081992 A2 AR 081992A2 AR P110102194 A ARP110102194 A AR P110102194A AR P110102194 A ARP110102194 A AR P110102194A AR 081992 A2 AR081992 A2 AR 081992A2
Authority
AR
Argentina
Prior art keywords
rifaximin
crystallization
production
carried out
water content
Prior art date
Application number
ARP110102194A
Other languages
English (en)
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33187382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR081992(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Publication of AR081992A2 publication Critical patent/AR081992A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12—Cooking devices
    • H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1236—Cooking devices induction cooking plates or the like and devices to be used in combination with them adapted to induce current in a coil to supply power to a device and electrical heating devices powered in this way
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12—Cooking devices
    • H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1245—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements
    • H05B6/1263—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements using coil cooling arrangements

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Electromagnetism (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe una forma pobremente cristalina del antibiótico rifaximina (INN), denominada rifaximina g que presenta un contenido de agua entre 1,0% y 2,0% y produce un difractograma de polvo por rayos X que presenta un perfil fundamentalmente amorfo y pocos picos significativos en valores de ángulos de difracción 2q de 5,0º; 7,1º, 8,4º. Esta forma es de utilidad en la producción de preparaciones medicinales para uso por vía oral y tópica y se pueden obtener por medio de un proceso de cristalización llevado a cabo por disolución en caliente de la rifaximina cruda en alcohol etílico y por cristalización del producto mediante la adición de agua a una temperatura determinada y por un período de tiempo determinado. La cristalización es seguida de un secado llevado a cabo bajo condiciones controladas hasta alcanzar un contenido de agua específico en el producto final.
ARP110102194A 2003-11-07 2011-06-23 FORMA POLIMORFICA g DE RIFAXIMINA, PROCESOS PARA SU PRODUCCION Y SUS COMPOSICIONES FARMACEUTICAS AR081992A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT002144A ITMI20032144A1 (it) 2003-11-07 2003-11-07 Forme polimorfe di rifaximina, processi per ottenerle e

Publications (1)

Publication Number Publication Date
AR081992A2 true AR081992A2 (es) 2012-10-31

Family

ID=33187382

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP040100781A AR043547A1 (es) 2003-11-07 2004-03-11 Formas polimorficas de rifaximina, procesos para su produccion y uso de las mismas en preparaciones medicinales
ARP110102194A AR081992A2 (es) 2003-11-07 2011-06-23 FORMA POLIMORFICA g DE RIFAXIMINA, PROCESOS PARA SU PRODUCCION Y SUS COMPOSICIONES FARMACEUTICAS
ARP110102193A AR081991A2 (es) 2003-11-07 2011-06-23 FORMA POLIMORFICA b DE RIFAXIMINA, PROCESOS PARA SU PRODUCCION Y SUS COMPOSICIONES FARMACEUTICAS

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP040100781A AR043547A1 (es) 2003-11-07 2004-03-11 Formas polimorficas de rifaximina, procesos para su produccion y uso de las mismas en preparaciones medicinales

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP110102193A AR081991A2 (es) 2003-11-07 2011-06-23 FORMA POLIMORFICA b DE RIFAXIMINA, PROCESOS PARA SU PRODUCCION Y SUS COMPOSICIONES FARMACEUTICAS

Country Status (37)

Country Link
US (5) US7045620B2 (es)
EP (6) EP1676847B1 (es)
JP (5) JP2005139161A (es)
KR (4) KR20050043589A (es)
CN (4) CN1613858A (es)
AR (3) AR043547A1 (es)
AT (3) ATE361927T1 (es)
AU (2) AU2004200964A1 (es)
BR (2) BRPI0402382A (es)
CA (2) CA2460384A1 (es)
CL (1) CL2004000498A1 (es)
CO (1) CO5560083A1 (es)
CY (3) CY1108017T1 (es)
DE (4) DE602004006367C5 (es)
DK (3) DK1676847T3 (es)
ES (3) ES2244364T3 (es)
HR (2) HRP20040265A2 (es)
IL (2) IL160798A0 (es)
IT (1) ITMI20032144A1 (es)
JO (1) JO2470B1 (es)
MA (1) MA27069A1 (es)
MD (1) MD3653G8 (es)
ME (1) ME00424B (es)
MX (2) MXPA04002353A (es)
NO (1) NO334950B1 (es)
NZ (1) NZ531622A (es)
PL (3) PL1676847T3 (es)
PT (3) PT1557421E (es)
RS (4) RS54571B1 (es)
RU (1) RU2270200C2 (es)
SI (3) SI1557421T1 (es)
TN (2) TNSN04044A1 (es)
TW (1) TWI285107B (es)
UA (1) UA86384C2 (es)
WO (1) WO2005044823A2 (es)
YU (1) YU24804A (es)
ZA (1) ZA200401948B (es)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US7923553B2 (en) * 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US7906542B2 (en) * 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20080262024A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
PT1698630E (pt) * 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
MX2009001342A (es) 2006-08-02 2009-08-31 Salix Pharmaceuticals Inc Composiciones y metodos para el tratamiento de proctosigmoiditis por radiacion.
ITMI20061692A1 (it) * 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
EP2069363B1 (en) * 2006-09-22 2013-03-20 Cipla Ltd. Rifaximin in an amorphous form
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
AU2016203925B2 (en) * 2007-07-06 2016-10-20 Lupin Limited Pharmaceutical compositions of rifaximin
JP5755878B2 (ja) * 2007-07-06 2015-07-29 ルパン リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ リファキシミンの薬剤組成物
ES2798253T3 (es) * 2007-07-06 2020-12-10 Lupin Ltd Composiciones farmacéuticas de rifaximina
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
US8067429B2 (en) * 2008-02-25 2011-11-29 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
PT2252148T (pt) * 2008-02-26 2020-01-23 Salix Pharmaceuticals Ltd Métodos de tratamento da síndrome do intestino irritável
US11779571B2 (en) * 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
HRP20140939T1 (hr) 2008-05-07 2014-11-21 Salix Pharmaceuticals, Ltd. Davanje preparata za äśišä†enje crijeva i antibiotika za lijeäśenje bolesti crijeva
AU2009297562B2 (en) 2008-09-26 2015-04-23 Alfasigma S.P.A. Agent for preventing and/or treating functional gastrointestinal disorder
US20100317681A1 (en) * 2009-06-15 2010-12-16 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
BRPI0920465A2 (pt) 2008-10-02 2018-03-20 Salix Pharmaceuticals, Inc. metodo de tratamento de encefalopatia hepática
US8916193B2 (en) 2008-12-10 2014-12-23 Cipla Limited Rifaximin complexes
IT1397617B1 (it) * 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
KR20190099100A (ko) 2009-06-02 2019-08-23 샐릭스 파마슈티컬스 리미티드 간성 뇌병증의 치료방법
NZ598671A (en) 2009-09-13 2014-02-28 Salix Pharmaceuticals Ltd Methods for treating irritable bowel syndrome (ibs)
RU2012121599A (ru) * 2009-10-27 2013-12-10 Люпин Лимитед Твердая дисперсия рифаксимина
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
EP2503989A2 (en) 2009-11-23 2012-10-03 Cipla Limited Topical foam composition
US8952159B2 (en) 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
AU2011218129A1 (en) 2010-02-18 2012-08-23 Board Of Regents Of The University Of Texas System Methods for treating infection
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
WO2011153444A1 (en) * 2010-06-03 2011-12-08 Salix Pharmaceuticals, Ltd New forms of rifaximin and uses thereof
CA2802874A1 (en) * 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
SMT202000390T1 (it) * 2010-07-12 2020-09-10 Salix Pharmaceuticals Inc Formulazioni di rifaximina e loro usi
WO2012035544A2 (en) 2010-09-13 2012-03-22 Sequent Scientific Ltd. A novel polymorphic form of rifaximin and process for its preparation
IT1403847B1 (it) 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012060675A1 (es) * 2010-11-05 2012-05-10 Interquim, S.A. De C.V. Proceso para la preparación de rifaximina amorfa
WO2012076832A1 (en) * 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
WO2012109605A2 (en) 2011-02-11 2012-08-16 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
CA2834829A1 (en) 2011-05-02 2012-11-08 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
WO2012155981A1 (en) 2011-05-19 2012-11-22 Friulchem Spa New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
ITMI20110890A1 (it) * 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
US20130184302A1 (en) * 2011-11-02 2013-07-18 Enoch Bortey Methods for treating irritable bowel syndrome (ibs) and infections
JP2013184902A (ja) * 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
US9359374B2 (en) 2012-06-13 2016-06-07 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
US9849090B2 (en) 2012-12-12 2017-12-26 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of rifaximin
US20160047819A1 (en) 2013-03-15 2016-02-18 Alfa Wassermann S.P.A. Method for diagnosing vaginal infections
US20160038468A1 (en) 2013-03-15 2016-02-11 Alfa Wassermann S.P.A. Rifaximin for use in the treating of vaginal infections
CN105324109A (zh) 2013-04-12 2016-02-10 意大利阿尔法韦士曼制药公司 Nsaid施用和相关的组合物、方法和系统
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
EP2927235B1 (en) 2014-03-31 2017-02-08 Euticals S.P.A. Polymorphic mixture of rifaximin and its use for the preparation of solid formulations
US9765088B2 (en) 2014-04-19 2017-09-19 Granules India Limited Process for the preparation of rifamycin derivatives
CA2947962C (en) 2014-05-04 2024-01-16 Salix Pharmaceuticals, Inc. Ibs microbiota and uses thereof
AU2015260837B2 (en) 2014-05-12 2019-02-28 Alfasigma S.P.A. New solvated crystal form of rifaximin, production, compositions and uses thereof
MX381919B (es) * 2014-06-30 2025-03-13 Salix Pharmaceuticals Inc Métodos para repetir tratamiento de síndrome del intestino irritable (ibs).
CN104083324B (zh) * 2014-07-10 2017-05-10 青岛动保国家工程技术研究中心有限公司 一种利福昔明的兽用悬乳剂及其制备方法和应用
EP2982764A1 (en) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identification of vaginal bacteria
CN104274391B (zh) * 2014-10-08 2017-02-01 哈尔滨坤盟医药科技有限公司 一种含利福昔明的药物制剂
WO2017021975A1 (en) * 2015-08-06 2017-02-09 Msn Laboratories Private Limited Process for the preparation of crystalline forms of rifaximin
HUE040253T2 (hu) 2016-03-24 2019-02-28 Sandoz Ag Rifaximin alfa&deltát tartalmazó gyógyászati készítmény
HUE044432T2 (hu) 2016-03-24 2019-10-28 Sandoz Ag Rifaximin alfá-t tartalmazó, hosszan eltartható kompozíció
US9988398B2 (en) * 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
CA3038312A1 (en) 2016-09-30 2018-04-05 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
CN106632396B (zh) * 2017-01-06 2019-01-11 成都樵枫科技发展有限公司 γ晶型利福昔明的制备方法和用途
CA3013161C (en) 2017-04-26 2020-03-24 Sandoz Ag Oral dosage form comprising rifaximin in form beta
RU2020102511A (ru) 2017-06-26 2021-07-27 Биофер С.П.А. Соединения пиридо-имидазо рифамицина в качестве антибактериального средства
US20220062183A1 (en) * 2018-12-19 2022-03-03 Friulchem S.P.A. Process for the manufacture of a tablet of rifaximin and tablet of rifaximin
CA3142214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
MX427410B (es) 2019-09-24 2025-10-13 Bausch Health Ireland Ltd Formulaciones liquidas de rifaximina
WO2021191312A1 (en) 2020-03-24 2021-09-30 Bausch Health Ireland Limited Methods of treating covid-19 with rifaximin
WO2021229480A1 (en) * 2020-05-15 2021-11-18 Atra Pharmaceuticals Limited Polymorph of rifaximin, process for the preparation thereof and pharmaceutical composition containing rifaximin
CA3184054A1 (en) 2020-06-26 2021-12-30 Jacob Cole Targeted release rifaximin compositions
US20230398102A1 (en) 2020-10-29 2023-12-14 Bausch Health Ireland Limited Rifaximin liquid formulations for use inthe treatment of sickle cell disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241785A (en) * 1978-07-24 1980-12-30 Peerless Of America, Inc. Heat exchangers and method of making same
IT1154655B (it) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) * 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
CA1215976A (en) 1984-05-15 1986-12-30 Vincenzo Cannata New process for the synthesis of imidazo rifamycins
IT1199413B (it) 1984-09-26 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
GB8816620D0 (en) * 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
CA2082809C (en) * 1990-06-29 1995-10-17 Marino Nebuloni Pure crystalline form of rifapentine
IL150524A0 (en) * 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
CA2426393C (en) * 2000-10-31 2012-05-29 Ciba Specialty Chemicals Holding Inc. Crystalline forms of venlafaxine hydrochloride
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20050262269A1 (en) 2004-05-20 2005-11-24 Pike Jimmy D System and method for information handling system PCI express advanced switching
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
EP2069363B1 (en) 2006-09-22 2013-03-20 Cipla Ltd. Rifaximin in an amorphous form
WO2008115572A1 (en) 2007-03-21 2008-09-25 Theraquest Biosciences, Inc. Methods and compositions of nsaids
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
ES2798253T3 (es) 2007-07-06 2020-12-10 Lupin Ltd Composiciones farmacéuticas de rifaximina
JP5755878B2 (ja) 2007-07-06 2015-07-29 ルパン リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ リファキシミンの薬剤組成物
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
WO2009047801A1 (en) 2007-10-10 2009-04-16 Lupin Limited Therapeutic combinations and compositions for the treatment of gastrointestinal disorders
US8067429B2 (en) 2008-02-25 2011-11-29 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof

Also Published As

Publication number Publication date
US20050272754A1 (en) 2005-12-08
ES2320161T3 (es) 2009-05-19
EP1557421A1 (en) 2005-07-27
CA2538546A1 (en) 2005-05-19
HK1073657A1 (en) 2005-10-14
US20050101598A1 (en) 2005-05-12
EP1557421B1 (en) 2007-05-09
ITMI20032144A1 (it) 2005-05-08
HK1092151A1 (en) 2007-02-02
ES2244364T1 (es) 2005-12-16
BRPI0407149A (pt) 2006-02-07
US7915275B2 (en) 2011-03-29
JP5199576B2 (ja) 2013-05-15
JP2011057698A (ja) 2011-03-24
EP1676848B1 (en) 2009-01-28
NZ531622A (en) 2004-10-29
PT1557421E (pt) 2007-07-31
RU2270200C2 (ru) 2006-02-20
AR081991A2 (es) 2012-10-31
AR043547A1 (es) 2005-08-03
EP1676848A1 (en) 2006-07-05
WO2005044823A2 (en) 2005-05-19
PL1676847T3 (pl) 2009-07-31
RS20060168A (sr) 2008-09-29
DE602004006367D1 (de) 2007-06-21
JP2011046738A (ja) 2011-03-10
JP2007509904A (ja) 2007-04-19
IL160798A0 (en) 2004-08-31
CA2538546C (en) 2011-04-19
DK1676847T3 (da) 2009-05-11
PL1557421T3 (pl) 2007-08-31
MD3653F2 (en) 2008-07-31
KR100883216B1 (ko) 2009-02-13
AU2004287601A1 (en) 2005-05-19
EP2210893A1 (en) 2010-07-28
CA2460384A1 (en) 2005-05-07
CO5560083A1 (es) 2005-09-30
DK1676848T3 (da) 2009-05-11
ATE421965T1 (de) 2009-02-15
DE602004019296D1 (de) 2009-03-19
DE04005541T1 (de) 2005-12-29
CL2004000498A1 (es) 2005-03-11
MA27069A1 (fr) 2004-12-20
CY1108017T1 (el) 2013-09-04
YU24804A (sh) 2006-08-17
ME00424B (me) 2011-10-10
CY1108964T1 (el) 2014-07-02
CN1886408B (zh) 2010-06-09
PL1676848T3 (pl) 2009-07-31
WO2005044823A3 (en) 2005-10-27
KR20050043589A (ko) 2005-05-11
EP1682556A2 (en) 2006-07-26
JP2014177500A (ja) 2014-09-25
RS20150292A1 (sr) 2015-10-30
HRP20060093A2 (en) 2006-05-31
DE602004019298D1 (de) 2009-03-19
PT1676848E (pt) 2009-04-09
IL174271A (en) 2010-12-30
ATE421966T1 (de) 2009-02-15
CN101260114B (zh) 2012-11-28
RU2004108953A (ru) 2005-10-27
PT1676847E (pt) 2009-04-09
US8404704B2 (en) 2013-03-26
US20080132530A1 (en) 2008-06-05
US20110160449A1 (en) 2011-06-30
TWI285107B (en) 2007-08-11
KR20070113327A (ko) 2007-11-28
RS54569B1 (sr) 2016-06-30
CY1108909T1 (el) 2014-07-02
RS54571B1 (sr) 2016-06-30
AU2004287601B8 (en) 2009-03-05
RS20150291A1 (sr) 2015-10-30
EP2208730A1 (en) 2010-07-21
ES2320160T3 (es) 2009-05-19
HRP20040265A2 (en) 2004-12-31
ZA200401948B (en) 2004-04-29
KR100855084B1 (ko) 2008-08-29
CN1886408A (zh) 2006-12-27
KR100867751B1 (ko) 2008-11-10
AU2004200964A1 (en) 2005-05-26
KR20060110737A (ko) 2006-10-25
BRPI0402382A (pt) 2005-06-28
DE602004006367C5 (de) 2019-04-04
TW200515913A (en) 2005-05-16
BRPI0407149A8 (pt) 2019-01-15
TNSN06069A1 (en) 2007-10-03
NO20061110L (no) 2006-04-19
US8173801B2 (en) 2012-05-08
DE602004006367T2 (de) 2007-09-06
MXPA04002353A (es) 2005-05-11
SI1557421T1 (sl) 2007-08-31
DK1557421T3 (da) 2007-09-17
AU2004287601B2 (en) 2009-02-26
CN101260114A (zh) 2008-09-10
ES2320160T4 (es) 2011-03-09
HRP20060093B1 (hr) 2015-12-18
JP5635376B2 (ja) 2014-12-03
CN101260115A (zh) 2008-09-10
RS54568B1 (sr) 2016-06-30
EP1676847A1 (en) 2006-07-05
IL174271A0 (en) 2006-08-01
CN1613858A (zh) 2005-05-11
US7045620B2 (en) 2006-05-16
MD3653G8 (ro) 2016-08-31
TNSN04044A1 (en) 2006-06-01
US20120059023A1 (en) 2012-03-08
UA86384C2 (uk) 2009-04-27
JP2005139161A (ja) 2005-06-02
SI1676848T1 (sl) 2009-06-30
MD20060080A (en) 2006-11-30
ATE361927T1 (de) 2007-06-15
MXPA06002644A (es) 2006-06-06
ES2244364T3 (es) 2007-12-01
HK1092150A1 (en) 2007-02-02
JO2470B1 (en) 2009-01-20
CN101260115B (zh) 2011-11-23
SI1676847T1 (sl) 2009-06-30
NO334950B1 (no) 2014-08-04
KR20070113326A (ko) 2007-11-28
EP1676847B1 (en) 2009-01-28

Similar Documents

Publication Publication Date Title
AR081991A2 (es) FORMA POLIMORFICA b DE RIFAXIMINA, PROCESOS PARA SU PRODUCCION Y SUS COMPOSICIONES FARMACEUTICAS
EP1698630A8 (en) New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
FR2923482B1 (fr) Nouvelle forme cristalline vi de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
EP2184354A4 (en) ISOPROPYL ALCOHOL-PRODUCING BACTERIUM AND METHOD FOR THE PRODUCTION OF ISOPROPYL ALCOHOL USED THEREOF
AR053147A1 (es) Forma cristalina del clorhidrato de ivabradina, un procedimiento para su preparacion y composiciones farmaceuticas que la contienen
IL175860A0 (en) Method for the production of a solid, orally applicable pharmaceutical composition
SI1752443T1 (sl) Nova kristalinična oblika V agomelatina, postopek za njeno pripravo in farmacevtski sestavki, ki jo vsebujejo
JO2216B1 (en) 5 chloro-3 (4-methane sulfonyl phenyl) -6-methyl- (2.3)
EP1993557A4 (en) Novel EPOPROSTSOLFORMULATION AND METHOD OF MANUFACTURING THEREOF
FR2889522B1 (fr) Nouvelle forme cristalline iv de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
TNSN07337A1 (en) Pharmaceutical composition comprising an indolylmaleimide derivative
HUP0301075A3 (en) Diphenyl ether derivatives, their use for preparation of pharmaceutical compositions and process for preparation the compounds
WO2005044824A3 (en) Processes for the preparation of highly pure 3-(2-substituted vinyl) cephalosporin
AU2003297367A1 (en) Process for preparing pharmaceutical formulations using supercritical fluids
AP2002002679A0 (en) Novel polymorph V of torasemide.
EP1646640A4 (en) PROCESS FOR PREPARING HIGH-PURITY 1-ANDROSTEN DERIVATIVES
PE20070548A1 (es) Formas cristalinas de la sal de di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico
PL2065035T3 (pl) Preparaty farmaceutyczne zawierające irbesartan
WO2009056617A3 (en) 4,4-disubstituted piperdines as renin inhibitors
MY144578A (en) New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
WO2005054211A8 (en) A method of purification of lorazepam
AR058282A1 (es) Forma cristalina purificada de cci-779, un proceso para la preparacion del mismo, un metodo para monitorear la cristalizacion del cci-779, un kit y una composicion farmaceutica que lo comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
DK2057148T3 (da) Amidinderivater af 2-heteroarylquinazoliner og quinoliner; potente analgetika og antiinflammatoriske midler
PT1646607E (pt) Método para a preparação de dexloxiglumida cristalina
WO2008027220A3 (en) Process and intermediates for the synthesis of (3-alkyl-5-piperidin-1-yl-3, 3a-dihydropyrazol0 [1, 5-a] pyrimidin-7-yl) -amino derivatives

Legal Events

Date Code Title Description
FC Refusal